No Surprises Act Has Little Impact on In-Network Imaging Claims
GAO reports the No Surprises Act had minimal impact on radiology, with inânetwork claims steady at ~99% and slight declines in payment rates.
Read moreMain Content
FDA Update on Oversight of AI-Enabled Healthcare Technologies
March 21, 2024
The U.S. Food and Drug Administration (FDA) published a paper March 15, to update the public about intra-agency activities to oversee artificial intelligence (AI)-enabled healthcare technologies. The paper summarizes priorities shared across the biologics, drugs and medical devices domains of FDA jurisdiction.
Four general focus areas are discussed: fostering collaboration with stakeholders; developing appropriate regulatory approaches; promoting development of standards and best practices; and supporting research on performance evaluation. Moving forward, the FDA intends to evolve its own regulatory approaches with the continued progression of AI tools.
For more information about various American College of Radiology®(ACR®) AI-specific initiatives, visit the ACR Data Science Institute®. For more information about FDA oversight and digital health policy, contact Michael Peters, ACR Senior Government Affairs Director.
